Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:moclobemide
|
| gptkbp:approvedBy |
1990s
|
| gptkbp:ATCCode |
N06AG02
|
| gptkbp:brand |
gptkb:Manerix
gptkb:Moclodura |
| gptkbp:chemicalFormula |
C13H17ClN2O2
|
| gptkbp:drugClass |
reversible inhibitor of monoamine oxidase A
|
| gptkbp:eliminationHalfLife |
2 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aurorix
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Meda_Pharmaceuticals
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B3 (Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness headache insomnia |
| gptkbp:usedFor |
gptkb:depression
gptkb:social_anxiety_disorder |
| gptkbp:bfsParent |
gptkb:Moclobemide
|
| gptkbp:bfsLayer |
7
|